1,7-phenanthroline has been researched along with Heart Disease, Ischemic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gurzenda, EM; Powell, SR; Wapnir, RA; Wingertzahn, MA | 1 |
| Au-Yeung, KK; O, K; Siow, YL; Zhu, DY | 1 |
2 other study(ies) available for 1,7-phenanthroline and Heart Disease, Ischemic
| Article | Year |
|---|---|
Promotion of copper excretion from the isolated rat heart attenuates postischemic cardiac oxidative injury.
Topics: Animals; Antidotes; Chelating Agents; Copper; Deferoxamine; Histidine; Male; Myocardial Ischemia; Myocardial Reperfusion Injury; Organometallic Compounds; Oxidative Stress; Phenanthrolines; Rats; Rats, Sprague-Dawley | 1999 |
Inhibition of stress-activated protein kinase in the ischemic/reperfused heart: role of magnesium tanshinoate B in preventing apoptosis.
Topics: Animals; Antioxidants; Apoptosis; Cell Nucleus; Heart; In Vitro Techniques; Magnesium; Male; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinases; Myocardial Ischemia; Myocardial Reperfusion; Myocardium; p38 Mitogen-Activated Protein Kinases; Phenanthrolines; Protective Agents; Rats; Rats, Sprague-Dawley; Statistics as Topic; Subcellular Fractions | 2001 |